Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BA.2.51NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.2.3.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
XATNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.3.11NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.2.85NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-18328.8US
BA.2.65NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.5.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BG.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-630.996US
BA.2.61NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BF.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.2.74NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.2.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BM.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.28NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.62NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.5.2.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.5.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.2.13.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BF.28NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-630.996US
BA.5.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BE.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-1549.93US
BE.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.5.1.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.26NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AE.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
N.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.36NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.407NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.423NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.281NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AE.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.230NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.535NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.564.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.345NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23143.5US
B.1.1.53NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.450NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.334NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.589NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.335NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.169NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.43NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.42NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AE.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used